Immune-mediated pathogenesis and development of autoimmunity in neurological manifestations of COVID-19

Immune-mediated pathogenesis and development of autoimmunity in neurological manifestations of COVID-19 - IPEA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024434

Enrollment

150

Registered

2021-02-05

Start date

2021-02-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LONG COVID, cognitive deficits during COVID-19 infection, psychiatric disease after COVID-19 infection, immunological marker and divergence in serum and cerebro spinal fluid during COVID infection U07.1

Interventions

Group 1: Depending on the time of presentation of Symptoms: acute onset, post COVID infection

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Informed consent no drug or alcohol addiction german language

Exclusion criteria

Exclusion criteria: not able to give informed consent, under-age, no juristical supervisor

Design outcomes

Primary

Measure	Time frame
Immunological biomarker and neurocognitive assessment scores	—

Countries

Germany

Contacts

Public ContactMonika Höveler

Uniklinik Köln Studienbüro Neurologie

monika.hoeveler@uk-koeln.de+49 221 478-87353

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026